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Background: Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and CTLA-4 was sug-
gested to yield clinical benefit over chemotherapy in malignant pleural mesothelioma (MPM), whereas aPD-
1 monotherapy failed to provide benefit in phase-III trials. Success of ICI depends on the presence and activa-
tion of tumor-specific T cells. Therefore, we investigated whether T-cell characteristics are underlying clinical
efficacy of ICI treatment in MPM.
Methods: Comprehensive immune cell profiling was performed on screening and on treatment peripheral
blood samples of mesothelioma patients treated with nivolumab (aPD-1) monotherapy (NCT02497508), or a
combination of nivolumab and ipilimumab (aCTLA-4) (NCT03048474).
Findings: aPD-1/aCTLA-4 combination treatment induced a profound increase in proliferation and activation
of T cells, which was not observed upon aPD-1 monotherapy. Moreover, patients that responded to combina-
tion treatment had low frequencies of naive CD8 T cells and high frequencies of effector memory CD8 T cells
that re-expressed RA (TEMRA) at screening. The frequency of Granzyme-B and Interferon-g producing TEM-
RAs was also higher in responding patients.
Interpretation: High proportions of TEMRAs and cytokine production by TEMRAs before treatment, was asso-
ciated with a better clinical outcome. TEMRAs, which likely comprise tumor-specific T cells, tend to require
blockage of both aPD-1 and aCTLA-4 to be reactivated. In conclusion, peripheral blood TEMRAs can play a
key role in explaining and predicting clinical benefit upon aPD-1/aCTLA-4 combination treatment.
Funding: Bristol-Myers Squibb sponsored NivoMes and INITIATE clinical trials and provided study drugs. No
external funding was applicable for the flow cytometric analyses of peripheral blood samples described in
this manuscript.
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Malignant pleural mesothelioma (MPM) is a malignancy arising
from the mesothelial cells in the pleural cavity, primarily caused by
asbestos exposure. Treatment options for MPM are very limited, as
platinum-based chemotherapy combined with an antifolate and the
optional addition of bevacizumab, are the only approved first-line
treatment for MPM. This treatment leads to a median overall survival(OS) of 1216 months [1,2]. Currently, no registered second-line
treatments are available, illustrating the urgent need for new treat-
ment options.
Immunotherapies aim for activation of the immune system, lead-
ing to efficient tumor-specific immune responses. In current clinical
practice, these therapies include monoclonal antibodies that block
inhibitory checkpoint receptors, i.e. programmed death 1 (PD-1), pro-
grammed death ligand 1 (PD-L1) and cytotoxic T lymphocyte associ-
ated antigen 4 (CTLA-4), thereby reinvigorating anti-tumor immune
responses [3]. So-called immune checkpoint inhibitor (ICI) treat-
ments have transformed the treatment landscape for various malig-
nancies, such as non-small cell lung cancer (NSCLC) and melanoma
[4,5].
Research in context
Evidence before this study
Immune monitoring, the assessment of peripheral blood
immune cell subsets, yielded valuable insight into peripheral
blood T-cell responses to immune checkpoint inhibitors (ICI) in
non-small cell lung cancer (NSCLC) and melanoma patients. We
searched Pubmed for scientific literature published between
Jan 1st 2010 and June 15th 2020 with the following terms:
“mesothelioma” AND (“PD-1” OR “PD-L1” OR “CTLA-4” OR
“checkpoint”) AND (“peripheral blood” OR “immune monitor-
ing”). No previous studies have assessed the peripheral blood
immune cell compartment upon ICI treatment in malignant
pleural mesothelioma (MPM).
Added value of this study
To our knowledge, we are the first to perform extensive
immune monitoring in MPM patients treated with both aPD-1
monotherapy and aPD-1/aCTLA4 combination therapy.
Recently, promising results of Checkmate-743 (NCT02899299)
demonstrated that treatment of MPM patients with nivolumab
and ipilimumab yielded a statistically significant and clinically
meaningful improvement in overall survival, compared to plati-
num-based chemotherapy plus pemetrexed. These results are
in contrast to the lack of benefit seen earlier in the PROMISE-
meso trial (NCT02991482) that investigated nivolumab mono-
therapy as compared to chemotherapy in MPM. We here pro-
vide a rationale for the benefit observed upon aPD-1/aCTLA-4
combination treatment in MPM by indicating differences in the
peripheral blood T-cell compartment in two phase II clinical tri-
als that assessed aPD-1 monotherapy and aPD-1/aCTLA4 com-
bination therapy.
Implications of all the available evidence
Combination checkpoint inhibition appears to be more effective
than their use alone in MPM, which was already shown in the
MAPS2 phase II randomized trial. Preliminary results of the Check-
mate-743 support this statement. These findings, combined with
our peripheral blood analyses, warrant further research into aPD-
1/aCTLA-4 combination in MPM with in-depth peripheral blood
and intratumoral T-cell characterization.
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pared to other malignancies. The DETERMINE trial showed no sur-
vival benefit of ipilimumab (anti-CTLA-4, aCTLA-4) monotherapy
over placebo [6] and pembrolizumab and nivolumab, both anti-PD-1
(aPD-1) monotherapies, demonstrated objective response rates
(ORR) of 21% and 26% in the KEYNOTE-028 and NivoMes trials
respectively [7,8]. Recently, the PROMISE-meso phase III randomized
trial (NCT02991482) failed to show improvement in PFS (progression-
free survival) and OS upon second line aPD-1 treatment (pembrolizu-
mab), as compared to single agent chemotherapy (institutional
choice of gemcitabine or vinorelbine) [9]. The lack of effective ICI
treatment in MPM is thought to be dependent on the small number
of tumor-infiltrating lymphocytes (TILs) in MPM [10,11] and the
immunosuppressive tumor microenvironment [12,13].
Combining aPD-1 and aCTLA-4 therapy has been shown to induce
synergistic effects in both preclinical and clinical studies [14,15].
Phase II trials in MPM also suggest improved clinical responses upon
combination ICI treatment, as the MAPS2 trial (nivolumab plus ipili-
mumab), the NIBIT-MESO trial (durvalumab (aPD-L1) plus tremeli-
mumab (aCTLA-4)) and the INITIATE trial (nivolumab plusipilimumab) reported better clinical responses upon combination ICI
treatment than reported by trials that investigated monotherapy
(nivolumab or pembrolizumab) [1618]. Recently, the first positive
results were announced for the Checkmate-743 [19], a phase III trial
that combined aPD-1 (nivolumab) with aCTLA-4 (ipilimumab) treat-
ment in previously untreated MPM patients. These results are very
promising, although the magnitude of the benefit is still awaited.
Success of aPD-1 treatment in NSCLC and melanoma is thought to
depend on pre-existing T-cell infiltration of the tumor [20], prolifera-
tion of peripheral PD-1-expressing CD8 T cells [21] and the ratio
between T-cell reinvigoration and tumor burden [22]. It remains
unclear whether the enhanced efficacy observed in ICI combination
treatment trials is due to an additive effect of the respective therapies
or truly depends on a novel immunological mechanism that is
engaged by targeting both PD-1 and CTLA-4 [23].
In order to dissect the immunological mechanisms responsible for
the clinical benefit from aPD-1 and aCTLA-4 therapy in MPM, we
aimed to investigate the characteristics of lymphocytes present in
peripheral blood of MPM patients treated with aPD-1 monotherapy
(nivolumab) in the NivoMes trial [8] and aPD-1 and aCTLA-4 combi-
nation therapy (nivolumab/ipilimumab) in the INITIATE trial [16]. We
specifically aimed to evaluate the T- and NK-cell compartment of the
peripheral blood, since prior studies established the value of this




Patients in this study were enrolled in either the NivoMes study
(NCT02497508) or the INITIATE study (NCT03048474). Both studies
were approved by the institutional review board of the Netherlands
Cancer Institute and in accordance with the Declaration of Helsinki.
All patients provided written informed consent before enrolment.
Collection and analysis of immune cell subsets in peripheral blood
were planned a priori as part of the two trials. Clinical results of the
NivoMes and INITIATE were previously published [8,16]. In summary,
in the NivoMes trial, 34 MPM patients progressing after at least one
cycle of platinum based chemotherapy, were treated with nivolumab
3 mg/kg every 2 weeks. In the INITIATE trial, 35 MPM patients pro-
gressing after at least one cycle of platinum based chemotherapy
were treated with nivolumab (240 mg flat dose every 2 weeks) plus
ipilimumab (1 mg/kg every 6 weeks up to four times). Peripheral
blood was collected from patients on the day of the first ICI treatment
and after six weeks of treatment. These samples correspond to the
‘screening’ and ‘on treatment’ time points. Response to treatment was
assessed according to modified RECIST criteria for mesothelioma
[25]. For comparison purposes, we decided to define responding
patients as having a complete response (CR), partial response (PR) or
stable disease (SD) at six months of follow up and non-responding
patients as having progressive disease (PD) at six months of follow
up. All patients in the ‘responder’ group experienced a PFS of six
months or longer and all patients in in the ‘non-responder’ group
progressed within six months.
2.2. Processing of peripheral blood
Fifty milliliters of blood was drawn at screening and on treatment
time points in EDTA tubes and processed. Peripheral blood mononu-
clear cells (PBMC) were isolated via standard density-gradient centri-
fugation using Ficoll-Hypaque (GE Healthcare, Chicago, IL, USA). Cells
were cryopreserved in 10% dimethylsulfoxide (Sigma-Aldrich, Saint
Louis, MO, USA), 40% FCS (Gibco, ThermoFisher, Waltham, MA, USA)
and RPMI (Invitrogen, ThermoFisher, Waltham, MA, USA) until fur-
ther use.
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Flow cytometry staining was performed on the cryopreserved
PBMC samples. After thawing of the PBMCs, cells were stimulated for
4 hours with phorbol 12-myristate 13-acetate and ionomycin (both
from Sigma-Aldrich, Saint Louis, MO, USA) and GolgiStop (BD Bio-
sciences, Franklin Lakes, NJ, USA), prior to continuation of the cyto-
kine staining. Supplementary table 1 lists the antibodies used for the
different stainings. First, extracellular markers were stained for
30 min at 4 °C. Secondly, the cells were stained with LIVE/DEAD Fix-
able Aqua Dead Cell Stain Kit (Invitrogen, ThermoFisher, Waltham,
MA, USA) for 10 min at 4 °C in order to identify dead cells. Next,
FoxP3 transcription factor fixation/permeabilisation mix (eBio-
science, ThermoFisher, Waltham, MA, USA) was used to fixate the
cells. Subsequently, intracellular markers were stained for 60 min at
4 °C. Data were acquired using an LSR II flow cytometer equipped
with three lasers. We used FlowJo v10 (BD Biosciences, Franklin
Lakes, NJ, USA) to analyze the data. Fig. 1A, C, D, F and H show the gat-
ing strategy. Specific maturation subsets of T cells were identified by
the cell surface markers CD45RA and CCR7. Fractions of
CD45RA+CCR7+ naive (N) T cells, CD45RACCR7+ central memory
(CM) T cells, CD45RACCR7 effector memory (EM) T cells and
CD45RA+CCR7 effector memory re-expressing RA (EMRA) T cells
were identified in both the CD4 and CD8 T-cell compartments.
2.4. Statistical analysis
Statistical analyses were performed in R version 4.0.2 and Graph-
Pad V8.0 (GraphPad, San Diego, CA, USA). P < 0.05 was considered
statistically significant. Significant differences between the groups
were determined with MannWhitney U tests (non-parametric,
non-paired data) and Wilcoxon signed rank tests (non-parametric,
paired data). P values were corrected for multiple testing, using the
Benjamini and Hochberg False Discovery Rate [26]. Log rank test was
used to compare Kaplan-Meier curves for PFS and OS. To stratify PFS
and OS for proportions of T-cell subsets, the median was used as a
cut off for high vs low proportions.
2.5. Role of funding sources
Bristol-Myers Squibb sponsored the clinical studies and provided
the study drugs in both the NivoMes and INITIATE clinical trials. The
analyses of peripheral blood mononuclear cells (PBMCs) by flow




Table 1 demonstrates the numbers of peripheral blood samples
available from the two clinical trials. Baseline characteristics are
shown for the patients of whom PBMCs were collected at screening
and at least 1 CT-scan for response evaluation was available.
3.2. Monotherapy with aPD-1 treatment does not induce T-cell
proliferation
In both NSCLC and melanoma, it was shown that aPD-1 treatment
increased proliferation of CD8 T cells in peripheral blood, and the
majority of these proliferating CD8 T cells were PD-1 positive [21,22].
We therefore analyzed whether aPD-1 monotherapy induced similar
changes in T- or NK cell subsets of MPM patients. No significant dif-
ferences were observed in the frequencies of T cells (Fig. 1B), T-cell
subsets (Fig. 1E, G, I), NK cells and NK T cells (Fig. 1B) between screen-
ing and 6 weeks after start of treatment. Surprisingly, aPD-1monotherapy also induced no increase in proliferation of T-cell sub-
sets, as assessed by Ki-67 expression, a cell cycle marker expressed
by cycling or recently divided cells (Fig. 1JL).
Next, we examined whether differences in the frequencies and
phenotype of T cells prior to treatment, could help identify patients
that responded to aPD-1 monotherapy. We found that MPM patients
with a response upon aPD-1 had slightly higher frequency of CM CD4
T cells, whereas all other T-cell frequencies were similar between
responding and non-responding MPM patients (Fig. 1MO). No
changes were found in the proportions of proliferating T- and NK
cells, assessed by Ki67 expression (data not shown).
Furthermore, no changes in the frequencies of PD-1, CD28, 4-1BB,
HLA-DR, inducible T-cell costimulator (ICOS), CD39, lymphocyte-acti-
vation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain
containing-3 (TIM-3) and CTLA-4 expressing T-cell subsets induced
by aPD-1 treatment or between responding and non-responding
patients were observed (data not shown).
In conclusion, aPD-1 treatment did not induce changes in the pro-
portion and proliferation of T-cell and NK cell subsets in MPM
patients. No major differences were found between responding and
non-responding patients prior to treatment.
3.3. aPD-1 and aCTLA-4 combination therapy promotes proliferation of
memory T-cell subsets
Secondly, we examined whether aPD-1 and aCTLA-4 combination
treatment induced proliferation and activation of T cells. We found
that combination treatment increased the proliferation of CM, EM
and EMRA CD4 T-cells and in naive and CM CD8 T-cells (Fig. 2EG).
This increase in proliferation was independent of clinical response
(Fig. 2 HJ). Furthermore, the frequency of CM, EM and EMRA CD4 T-
cell subsets, and CM and EM CD8 T cells that expressed ICOS
increased upon combination therapy, indicating that combination
therapy induced T-cell activation (Fig. 3AC). In the CD4 T-cell com-
partment, this activation was most prominent in non-responding
patients (Fig. 3D). Combination treatment did not induce differences
in the frequency of the activation and inhibitory markers CD28, 4-
1BB, HLA-DR, PD-1, LAG-3, TIM-3, CD39 and CTLA-4 in both CD4 and
CD8 T-cell subsets (data not shown).
In conclusion, combining aPD-1 and aCTLA-4 treatment induced
proliferation and activation of memory T-cell subsets, however, this
proliferation was independent of clinical response.
3.4. MPM patients responding to combined aPD-1 and aCTLA-4
treatment showed an altered distribution of CD8 T-cell subsets prior to
treatment
We investigated whether the frequency or phenotype of T-cell
subsets was different prior to treatment in patients that responded,
compared to patients that did not respond to aPD-1 and aCTLA-4
combination treatment. MPM patients that responded had a different
distribution of their T-cell compartment prior to treatment, with sig-
nificantly lower frequencies of naive and CM CD8 T cells and a higher
frequency of EMRA CD8 T cells (Fig. 4AC). Log rank test revealed
that patients with a high EMRA CD8 T-cell proportion (cut-off based
on the median proportion) at screening, had a significantly longer
PFS upon combination treatment (median PFS of 13.1 vs 3.5 months,
p = 0.045). Although the OS curves also appeared to differ (median OS
of 25.9 vs 10.2 months), this difference was not statistically signifi-
cant (Fig. 4D and E). Upon further characterization of these EMRA
CD8 T cells, we found that the frequency of Granzyme-B and IFNg-
expressing EMRA CD8 T cells was increased in responding patients
(Fig. 5A and B). Increased cytokine expression was also observed in
CM CD8 T cells and EM CD8 T cells (Fig. 5A and B). High or low pro-
portion of Granzyme-B positive EMRA CD8 T cells (cut-off based on
the median proportion) prior to treatment was used to stratify PFS
Fig. 1. T- and NK-cell characteristics before and during aPD-1 monotherapy
(a, c, d, f, h) Gating strategy for NK-cells (a), T-cells (c), CD4 T-cells subsets (d), CD8 T-cells subsets (f) and Treg subsets (h) respectively. (b, e, g, i) Percentage of T-and NK-cell
subsets (b), CD4 T-cell subsets (e), CD8 T-cells subsets (g) and Treg subsets (I) respectively, at screening and on-treatment time points. (j, k, l) Percentage of Ki67+ CD 4 T-cell subsets
(j), Tregs subsets (k) and CD8 T-cell subsets (l) respectively, at screening and on-treatment time points. (m, n, o). Paired samples are shown connected by black lines. Percentage of
CD4 T-cell subsets (m), Treg subsets (n) and CD8 T-cell subsets (o) respectively, at the screening time point in responding and non-responding patients. Bars depict mean values
with standard error of the mean.
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Table 1
Characteristics of patients included in translational analysis.
NivoMes INITIATE
Patients screened 38 38
Included, received at least 1 cycle of treatment 34 35
At least 1 CT for response evaluation available 33 34
At least 1 PBMC sample for FCM available at screening or on-treatment time point 31 38
PBMC sample at screening time point available 24 38
PBMC sample at screening time point and response evaluation available 23 32
Baseline characteristics
n 23 32
Age (years) (range) 67 (6273) 65 (6272)
Gender (%) Male 19 (17.4%) 24 (75%)
Female 4 (82.6%) 8 (25%)
Histological subtype (%) Epithelioid 21 (91.3%) 28 (87.5%)
Sarcomatoid 2 (8.7%) 2 (6.2%)
Mixed 0 (0%) 2 (6.2%)
WHO (%) 0 10 (43.5%) 11 (34.4%)
1-2 13 (56.5%) 21 (65.6%)
6 months response (%) CR 0 (0%) 0 (0%)
PR 6 (26.1%) 12 (37.5%)
Epithelioid 6 (100%) 11 (91.7%)
Sarcomatoid 0 (0%) 1 (8.3%)
Mixed 0 (0%) 0 (0%)
SD 1 (4.3%) 4 (12.5%)
Epithelioid 1 (100%) 2 (50%)
Sarcomatoid 0 (0%) 1 (25%)
Mixed 0 (0%) 1 (25%)
PD 16 (69.6%) 16 (50%)
Epithelioid 14 (87.5%) 15 (93.8%)
Sarcomatoid 2 (12.5%) 0 (0%)
Mixed 0 (0%) 1 (6.2%)
PFS (months) (95% CI) 2.44 (1.310.0) 6.25 (4.111.0)
OS (months) (95% CI) 11.5 (5.121.6) 23.0 (12.5-not reached)
J.M. Mankor et al. / EBioMedicine 62 (2020) 103040 5and OS. Median PFS was 10.8 months vs 3.5 months for the high vs
low groups and median OS was 32.6 vs 10.2 months. Log rank test
did not reveal any significant differences between the two curves for
both PFS and OS, although a clear trend was seen in the OS curves.
In conclusion, patients that responded to combined treatment
with aPD-1 and aCTLA-4 had a different T-cell distribution, in particu-
lar more EMRA CD8 T cells and less naive CD8 T cells, prior to treat-
ment. The frequency of cytokine-expressing memory CD8 T cells was
increased in responding patients, indicating that these memory CD8
T cells are more functionally active.
4. Discussion
Recently, the first positive results were announced for the Check-
mate-743 trial, demonstrating that combining aPD-1 and aCTLA-4 ther-
apy led to improved OS in MPM, as compared to chemotherapy [19]. In
contrast, aPD-1 monotherapy failed to improve PFS and OS [9]. Under-
standing the immunological mechanisms explaining why combination
therapy of aPD-1 and aCTLA-4 is effective and monotherapy is not, is
thus vital to select effective treatment options for MPM. To the best of
our knowledge, we are the first to investigate T-cell characteristics of
MPM patients treated with either aPD-1 monotherapy or aPD-1/aCTLA4
combination therapy, treated during two ICI trials [8,16].
Using comprehensive immune monitoring, we demonstrate that
combining aPD-1 with aCTLA-4 treatment strongly induces memory
T-cell proliferation and activation of both CD4 and CD8 T cells. Higher
frequencies of ICOS-expressing CD4 T cells were only observed in the
combination therapy. Since this proliferation and activation was irre-
spective of clinical response, these results could indicate that aPD1/
aCTLA-4 treatment induces proliferation and activation of bystander,
non-tumor specific T cells, which lack the ability to respond to tumor
antigens and do not result in a successful anti-tumor immune
response. However, the distribution of T-cell subsets prior to treat-
ment was different in MPM patients with a clinical response tocombined aPD-1 and aCTLA-4 treatment. Herein, we found increased
frequencies of EMRA CD8 T cells (TEMRAs) at the cost of naive CD8 T
cells. Survival analysis also showed that PFS was significantly longer
in patients with high frequencies of TEMRAs prior to treatment. Fur-
thermore, in responding patients, we found higher frequencies of
TEMRAs expressing Granzyme-B and IFNg . Thus, combined aPD-1/
aCTLA-4 treatment was associated with the activation and prolifera-
tion of memory T cells, but only MPM patients with high frequencies
of TEMRAs prior to start of treatment, did benefit. The beneficial pres-
ence of TEMRAs could indicate that TEMRAs in particular comprise
tumor-specific memory T cells that can be reinvigorated by combina-
tion treatment, but not by aPD-1 monotherapy, as these associations
were not found in the aPD-1 monotherapy study.
Our results are supported by several studies investigating memory
CD8 T-cell biology, both in general and in relation to ICI treatment. Char-
acterization of TILs in melanoma patients treated with combined aPD1/
aCTLA-4 therapy revealed that tumors of responding patients harbored
an effector memory T-cell population (CD8+ EOMES+CD69+CD45RO+)
that was less abundant in non-responding patients [27]. Wei et al.
revealed that dual blockade of PD-1 and CTLA-4 engages biological path-
ways partly different from aPD-1 monotherapy [28]. Combined aCTLA-1/
aPD-1 treatment increased the frequencies of a terminally differentiated
TBET+EOMES+ CD8 T-cell subset in peripheral blood of melanoma
patients, whereas aPD-1 monotherapy did not. Therefore, the authors
speculated that combination therapy may be sufficient to attenuate or
even reverse T-cell exhaustion. Both studies demonstrated that the com-
bination of aPD1/aCTLA4 has a distinct effect on borderline terminally
differentiated memory T-cells, which was not observed upon aPD-1
monotherapy.
Our findings indicate that combination ICI treatment, in contrast
to aPD-1 monotherapy, is able to reactivate these crucial TEMRA cells.
Further research should provide mechanistic insight in how com-
bined aPD-1 and aCTLA-4 treatment reactivates TEMRAs and should
indicate their specificity.
Fig. 2. T- and NK-cell characteristics before and during aPD-1/CTLA-4 combination therapy
(a, b, c, d) Percentage of T-and NK-cell subsets (a), CD4 T-cell subsets (b), Treg subsets (c) and CD8 T-cells subsets (d) respectively, at screening and on-treatment time points.
(e, f, g) Percentage of Ki67+ CD 4 T-cell subsets, (TCM p = 0.003, TEM p = 0.007, TEMRA p = 0.028) (e), Tregs subsets (f) and CD8 T-cell subsets (TN p = 0.036, TCM p = 0.03,) (g) respec-
tively, at screening and on-treatment time points. (h, i, j) Comparison between responding (R) and non-responding (NR) patients for the percentage of Ki67+ CD 4 T-cell subsets
(TCM R p = 0.01, TCM NR p = 0.04, TEM R p = 0.01) (h), Tregs subsets (i) and CD8 T-cell subsets (j) respectively, at screening and on-treatment time points. Paired samples are shown
connected by black lines in each graph. Significance (Wilcoxon signed-rank test for paired analysis of screening and on-treatment samples and MannWhitney U test for compari-
son of response groups) is shown in each graph, with * p < 0.05 and ** p< 0.01. P values were corrected for multiple testing, using the Benjamini and Hochberg False Discovery Rate.
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patients, we did not observe increases in T-cell proliferation upon
aPD-1 monotherapy in MPM patients. These studies reported that
the increase in proliferation peaked 3 weeks after start of treatment,
and declined afterwards [21,22]. As we evaluated immunological dif-
ferences 6 weeks after start of treatment, we were most likely too
late to assess the effects of aPD-1 monotherapy. However, these dif-
ferences could also be dependent on tumor type, as aPD-1 therapy
depends on pre-existing tumor-specific PD-1-expressing cells, which
could be more frequent in NSCLC and melanoma as compared toMPM. Moreover, it has been described earlier that aPD-1 and aCTLA-
4 therapy induced longer lasting transcriptional alterations as com-
pared to aPD-1 monotherapy [29], potentially enabling us to detect
changes in T-cell characteristics in combination ICI treatment in
peripheral blood at a later point in time.
It is important to highlight that the immunological differences
found in the two treatment modalities, although they clearly seem to
fit response observations, could still be of a phenomenological nature.
Thus, our results do not warrant any general conclusions on differen-
ces in ICI monotherapy and combination therapy in tumor types
Fig. 3. Percentage of ICOS+ T cell subsets before and during aPD-1/CTLA-4 combination therapy
(a, b, c) Percentage of ICOS+ CD 4 T-cell subsets (TCM p = 0.002, TEM p = 0.003, TEMRA p = 0.004) (a), Tregs subsets (b) and CD8 T-cell subsets (TCM p = 0.003, TEM p = 0.012) (c)
respectively, at screening and on-treatment time points. (d, e, f) Comparison between responding (R) and non-responding (NR) patients for the percentage of ICOS+ CD 4 T-cell sub-
sets (TN NR p = 0.01, TCM NR p = 0.02, TEM NR p = 0.03, TEMRA NR p = 0.01 (d), Tregs subsets (nTreg NR p = 0.01) (e) and CD8 T-cell subsets (TCM R p = 0.03) (f) respectively, at
screening and on-treatment time points. Paired samples are shown connected by black lines in each graph. Significance (Wilcoxon signed-rank test) is shown in each graph, with *
p < 0.05 and ** p < 0.01. P values were corrected for multiple testing, using the Benjamini and Hochberg False Discovery Rate
J.M. Mankor et al. / EBioMedicine 62 (2020) 103040 7other than MPM. Given the limited number of patients analyzed in
these studies and the limited number of responding patients, espe-
cially in the aPD-1 monotherapy study, our findings need to be vali-
dated in a larger and independent MPM patient cohort. Investigating
the immunological changes induced by ICI treatment on multiple
time points after start of treatment will also provide insight into the
duration of these immunological changes upon different ICI treat-
ments, and enable the comparison between MPM and other malig-
nancies. Furthermore, it is not known whether changes in peripheral
T-cell subsets reflect changes in the tumor microenvironment (TME)
in MPM, and whether tumor specific T cells migrated from theperipheral blood into the TME or vice versa. We are also aware of the
fact that nivolumab was administered in a weight dependent dose of
3 mg/kg every 3 weeks in NivoMes, thus modestly differing from the
fixed dose of 240 mg/kg every 3 weeks that was administered in INI-
TIATE. However, since Selby et al. [15] demonstrated that no signifi-
cant alterations in lymphocyte subsets were seen upon different
dosing regimens of nivolumab in macaques, we believe that the
immune cell alterations described in this manuscript are most likely
not caused by dosing differences. At last, it is important to keep in
mind that the presumed similarity between pembrolizumab and
nivolumab is subject to an ongoing debate in MPM, especially since
Fig. 4. Comparison of T-cell characteristics before aPD-1/CTLA-4 combination therapy in responding and non-responding patients
(a, b, c) Percentage of CD4 T-cell subsets (a), Treg subsets (b) and CD8 T-cell subsets (TN p = 0.017, TCM p = 0.008, TEMRA p = 0.028) (c) respectively, at the screening time point
in responding and non-responding patients. Bars depict mean values with standard error of the mean. Significance (MannWhitney U test) is shown in each graph, with * p < 0.05
and ** p < 0.01. P values were corrected for multiple testing, using the Benjamini and Hochberg False Discovery Rate. (d, e) EMRA CD8 T-cells proportions prior to treatment were
used to stratify progression-free survival (PFS) (d) and overall survival (OS) (e). Median proportion of EMRA CD8 T cells was used as a cut off between the ‘high’ vs ‘low’ group. Statis-
tical significance of the difference between the two KaplanMeier curves was tested by log rank test with p = 0.045 for PFS (median PFS of 3.5 vs 13.1 months) and p = 0.086 for OS
(median OS of 10.2 vs 25.9 months).
8 J.M. Mankor et al. / EBioMedicine 62 (2020) 103040several studies in non-Caucasian populations demonstrated ORRs to
nivolumab that appear to be higher than what was seen in studies
performed in Europe and the United States [30,31].
In conclusion, the combined treatment of aPD-1 and aCTLA-4
induced a robust T-cell proliferation and activation in MPM
patients, whereas aPD-1 monotherapy did not. The absence of a
correlation to clinical response could indicate that these are
bystander T-cells, unable to react to tumor-antigens. High propor-
tions of TEMRAs that expressed cytokines, prior to treatment,
were associated with a better clinical outcome to combination
therapy, likely because TEMRAs comprise tumor-specific T cells.
This also suggests that TEMRAs can only be reactivated upon com-
bined blockade of both aPD-1 and aCTLA-4. These findings have
important implications for future clinical trial design. First, it pro-
vides an explanation for the discouraging results of aPD-1 mono-
therapy in MPM, since aPD-1 monotherapy appears unable to
reinvigorate tumor-specific terminally differentiated memory CD8
T cells in MPM. Second, it grants directions for future research,
since aPD-1/aCTLA-4 appears to be a promising treatment modal-
ity for MPM, especially now that we are able to select patients up
front that are likely to respond. And, finally, it provides a rationale
for studying the efficacy of combining these treatments with vacci-
nation strategies like dendritic cell vaccines in non-responding
patients, since these vaccines have been shown to induce tumor
specific T cells [32].Contributors
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tively, at the screening time point in responding and non-responding patients. Bars depict mean values with standard error of the mean. Significance (MannWhitney U test) is
shown in each graph, with * p< 0.05 and ** p< 0.01. P values were corrected for multiple testing, using the Benjamini and Hochberg False Discovery Rate. (c, d) Proportions of Gran-
zyme-B+ EMRA CD8 T-cells prior to treatment were used to stratify progression-free survival (PFS) (d) and overall survival (OS) (e). Median proportion of Granzyme-B+ EMRA CD 8 T
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